Table 1.

Baseline characteristics of the patient with cerebral venous sinus thrombosis.

Characteristics	LMWH	LMWH	P-value
	n=26	n=18
	n (%)
Age	1.37±10.3	37.66±20.9	0.91
Gender (female)	22 (84.6)	13 (72.2)	0.31
Time to treatment, week (median)	1.61±0.98	1.82±0.92	0.46
Clinical presentation
Headache	21(80.8)	17 (94.4)	0.37
Seizure	12 (46.2)	6 (33.3)	0.39
Loss of consciousness	6 (23.1)	4 (22.2)	0.99
Papilledema	15 (57.7)	10 (55.6)	0.88
Aphasia	4 (15.4)	1 (5.65)	0.63
Motor deficit	10 (38.5)	7 (38.9)	0.97
Sensory deficit	9 (34.6)	7 (38.9)	0.77
Mental disorder	5 (19.2)	4 (22.2)	0.99
Ocular palsy	4 (15.4)	3 (16.7)	0.99
Risk factor
Fasting	8 (30.8)	3 (16.7)	0.48
Thrombophilia	4 (15.4)	2 (11.1)	0.99
Female-specific	16 (61.5)	12 (66.6)	0.22
Not identified	7 (26.9)	3 (16.7)	0.48
Number of sinus involved
≤2	20 (76.9)	11 (61.1)	0.25
>2	6 (23.1)	7 (38.9)
CVST type
Dural sinus	25 (96.2)	18 (100)	0.99
Cortical vein	5 (19.2)	2 (11.1)	0.68
Jugular vein	0 (0.0)	2 (11.1)	0.16
Deep vein	6 (23.1)	3 (16.7)	0.71
Brain MRI
Infarct	6 (23.1)	4 (22.2)	0.99
Hemorrhage	5 (19.2)	4 (22.2)	0.99
No parenchyma lesions	15 (57.7)	10 (55.6)	0.88
Duration admission	11.1±4	11.3±5.2	0.84
Duration of heparin treatment	6.8±2.1	7.5±2.2	0.36
CVST - cerebral venous sinus thrombosis, UFH - unfractionated heparin, LMWH - low-molecular-weight heparin